Get the Stockscreener App
754.87
0.24%
1.84
After Hours:
754.87
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy - Yahoo Finance
Cell And Gene Therapy Market Growth in Future Scope 2024-2031 | - openPR
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock? - MSN
Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Regeneron Pharmaceuticals Unusual Options Activity - Benzinga
Ex-Regeneron Director Says FMLA Suit Should Stay In Court - Law360
Regeneron questions Dupixent marketing deal with Sanofi - Westfair Online
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.
Fmr LLC Has $10.89 Billion Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dai ichi Life Insurance Company Ltd Sells 2,383 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Bank of Montreal Can - MarketBeat
The Manufacturers Life Insurance Company Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cerity Partners LLC Acquires 2,423 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sarcopenia Market on Track for Major Expansion by 2034, According to DelveInsight | Biophytis, MyMD Pharma, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals - The Globe and Mail
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
The Law Offices of Frank R. Cruz Continues Investigation of - GlobeNewswire
Sarcopenia Market on Track for Major Expansion by 2034, - openPR
Loomis Sayles & Co. L P Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Harvest Fund Management Co. Ltd - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Daiwa Securities Group Inc. - MarketBeat
Regeneron Pharmaceuticals (MEX:REGN) Enterprise Value : MXN1,511,984 Mil (As of Nov. 25, 2024) - GuruFocus.com
Age-related Macular Degeneration (AMD) Drugs Market Top - openPR
Regeneron's fourth-quarter sales climb 29 percent, beating estimates - FirstWord Pharma
Swedbank AB Purchases 13,705 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 15% CAGR over the last five years - Yahoo Finance
Pacer Advisors Inc. Has $20.54 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Prospera Financial Services Inc Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Icon Wealth Advisors LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Massachusetts Financial Services Co. MA Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings - Simply Wall St
Thompson Siegel & Walmsley LLC Sells 1,124 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intech Investment Management LLC Sells 3,240 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Advisors Asset Management Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Thrivent Financial for Lutherans Purchases 1,306 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (MIC:REGN-RM) EV-to-Revenue : 2.99 (As of Nov. 20, 2024) - GuruFocus.com
(REGN) On The My Stocks Page - Stock Traders Daily
Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron - Barchart
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myopic Macular Degeneration Market Forecasted to Surge - openPR
Retireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Multiple Myeloma Market on Track for Major Expansion by 2034, - openPR
Breakthrough Therapy BT Designation Market Is Booming - openPR
Artery Stenosis Drug Market Insights Comprehensive Trends, - openPR
Retinal Biologics Market: Future Scope, Growth Potential, - openPR
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron: The Biotech Stock To Buy Now (NASDAQ:REGN) - Seeking Alpha
Eczema Therapeutics Market 2024-2031 Revenues Will Increase - openPR
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Insider Monkey
Familial Hypercholesterolemia Market Forecasted to Surge - openPR
Quest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Macular Degeneration Treatment Market Is Expected To Reach - openPR
10 Biggest Biotechnology Companies - Investopedia
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Yahoo Finance
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
0.54%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):